Ⓐ
PeptiBrief
Evidence Library
randomized_controlled_trial · 2019

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials

Kingsberg SA, Clayton AH, Portman D, et al. · Obstetrics & Gynecology
highPMID · 31599840Verified
View source
Plain-English summary

The trials reported improved sexual desire and reduced distress compared with placebo in the studied population.

Population
Premenopausal women with HSDD
Intervention
Bremelanotide versus placebo
Outcomes measured
Sexual desire and related distress
Key findings
Supported efficacy for the approved indication.
Limitations
Population and indication were specific; results cannot be generalized to all libido concerns.
Risk of bias
Industry-sponsored clinical development; randomized placebo-controlled design.
Citation
Kingsberg SA, Clayton AH, Portman D, et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology
Linked peptides in the PeptiBrief database
ImportantPeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.